You are here:
Wegovy
Extension of indication to include risk reduction of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and BMI ≥27 kg/m2.
No estimate possible yet
Registration application pending
Semaglutide
Metabolism and Endocrinology
Indication extension
Other metabolism and Endocrinology
Novo Nordisk
GLP-1 receptor agonist
Subcutaneous
Injection
Normal trajectory
October 2023
August 2024
There is currently nothing known about the expected patient volume.
There is currently nothing known about the expected cost.
There is currently nothing known about the possible total cost.
There is currently nothing known about off label use.
There is currently nothing known about indication extensions.
There is currently no futher information available.
Understanding of expected market entry of innovative medicines